Non Hodgkin's Lymphoma


Novel SCT protocols

The field of Stem Cell Transplants is expanding rapidly. What was once reserved for only the most desperate patients with aggressive lymphoma has become a standard therapy for virtually any type of Lymphoma.

In the past patients with indolent types of lymphoma such as follicular NHL rarely underwent a Stem Cell Transplant until they had tried at least 3-4 other therapies. The wisdom of the time was that this very aggressive treatment should not be used when less toxic and less risky treatments were still available.

This thinking has changed quite dramatically in the past few years. Since about the year 2000 there have been many novel new approaches to SCT's that combine immunotherapy in the form of Rituxan, Zevalin, Bexxar, Interferon and others, which have proven to dramatically improve the progression free survival for patients with indolent lymphoma. It is still too early to say what effect these new approaches will have on long term survival, but the early results are quite impressive. Immunotherapy combined with chemotherapy is becoming the wave of the future.

Below are some selected medical abstracts about some of these new SCT protocols. These will be updated from time to time to keep them current.  I will begin by posting a link to an abstract that doesn't deal with SCT's but does deal with the role that Rituxan has had in showing the first change for the better for follicular lymphoma in more than 20 years.

Note: Although the abstracts presented below all deal with immunotherapy based SCT's for low-grade lymphomas the results for those with aggressive lymphoma are equally impressive.

  1. Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma Treated With Rituximab Plus CHOP Chemotherapy: 9-Year Follow-Up

  2. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas

  3. High Dose Therapy / ASCT with Rituximab for In-Vivo Purging and Post-ASCT Consolidation in Relapsed Follicular Lymphoma Achieves Prolonged Clinical and Molecular Remissions

  4. Rituximab Given after High Dose Therapy and Autologous Stem Cell Transplantation Induces Durable Clearance of Minimal Residual Disease in about Half of the Patients with Follicular Non Hodgkin's Lymphoma: 36 Months Results of a Multicenter Open Label Phase II Trial

  5. High Dose Therapy/ASCT Consolidated by Rituximab and or Interferon Immunotherapy for Relapsed Follicular Lymphoma Achieves Durable Molecular Remissions and Improved Progression Free Survival

  6. Rituximab and Peripheral Blood Stem Cell Transplantation Produces Durable Remissions in Patients with Low Grade and Mantle Cell Lymphoma

  7. Dose Finding Trial of Yttrium 90 (90Y) Ibritumomab Tiuxetan with Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL).

  8. Intense Immunochemotherapy (IC) and Autologous Stem Cell Transplant (ASCT) for Untreated Patients (pts) with Mantle Cell Lymphoma (MCL)



SCT patient journals
Stem Cell Harvest
Take to the Hospital
The Neutropenic Diet
SCT for Dummies
Re-immunization schedule

© 2005 NHL Cyberfamily All Rights Reserved.
Web design by
Long2 Consulting